Allogene Therapeutics - ALLO Stock Forecast, Price & News

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Allogene Therapeutics Trading Up 3.1 %

Shares of ALLO traded up $0.52 during mid-day trading on Friday, reaching $17.09. 91,706 shares of the stock traded hands, compared to its average volume of 1,596,743. Allogene Therapeutics has a 1 year low of $6.43 and a 1 year high of $27.86. The firm has a fifty day moving average price of $12.13 and a 200 day moving average price of $10.06. The company has a market cap of $2.46 billion, a price-to-earnings ratio of -7.57 and a beta of 0.56.

Allogene Therapeutics (NASDAQ:ALLO - Get Rating) last announced its earnings results on Tuesday, August 9th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.61) by $0.09. Allogene Therapeutics had a negative net margin of 124,571.27% and a negative return on equity of 34.73%. During the same period last year, the firm earned ($0.53) earnings per share. On average, sell-side analysts anticipate that Allogene Therapeutics will post -2.59 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. The Goldman Sachs Group raised shares of Allogene Therapeutics from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $9.00 to $32.00 in a report on Friday, July 15th. Robert W. Baird initiated coverage on shares of Allogene Therapeutics in a research note on Thursday, June 2nd. They issued a "neutral" rating and a $11.00 price objective for the company. Oppenheimer reduced their price objective on shares of Allogene Therapeutics from $40.00 to $35.00 and set an "outperform" rating for the company in a research note on Wednesday. Finally, Raymond James lowered shares of Allogene Therapeutics from an "outperform" rating to a "market perform" rating in a research note on Wednesday. Three analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $27.75.

Insider Buying and Selling

In related news, CMO Rafael Amado sold 11,500 shares of the company's stock in a transaction on Thursday, May 19th. The shares were sold at an average price of $7.40, for a total value of $85,100.00. Following the completion of the transaction, the chief marketing officer now directly owns 546,257 shares in the company, valued at $4,042,301.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Allogene Therapeutics news, Director Owen N. Witte sold 10,000 shares of the business's stock in a transaction on Wednesday, June 22nd. The shares were sold at an average price of $11.76, for a total value of $117,600.00. Following the completion of the sale, the director now directly owns 233,271 shares of the company's stock, valued at $2,743,266.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CMO Rafael Amado sold 11,500 shares of the business's stock in a transaction on Thursday, May 19th. The stock was sold at an average price of $7.40, for a total transaction of $85,100.00. Following the completion of the sale, the chief marketing officer now directly owns 546,257 shares of the company's stock, valued at $4,042,301.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 27,500 shares of company stock worth $271,880. Corporate insiders own 26.30% of the company's stock.